Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STEVEN R LEIBOWITZ

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1053323600
CMS profile
229253
Location
RIVER EDGE, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$778.83

57 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $778.83 57

By paying entity

PY2024 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 57 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STEVEN R LEIBOWITZ

NPI 1053323600 · CMS profile ID 229253

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

RIVER EDGE, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 57 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1053323600?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STEVEN R LEIBOWITZ, NPI 1053323600, CMS profile ID 229253. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 57 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1053323600?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). STEVEN R LEIBOWITZ, NPI 1053323600, CMS profile ID 229253. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 57 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1053323600?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
STEVEN R LEIBOWITZ, NPI 1053323600, CMS profile ID 229253, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 57 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1053323600?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

57 matching records · $778.83 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 57 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 57.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Takeda Pharmaceuticals U.S.A., Inc. $16.9912/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137617464 CMS
Janssen Biotech, Inc. $16.6112/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078370435 CMS
Janssen Biotech, Inc. $16.8012/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078370516 CMS
Intercept Pharmaceuticals, Inc. $19.3411/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113643297 CMS
ABBVIE INC. $15.6111/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104159224 CMS
ABBVIE INC. $0.6611/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104159226 CMS
ABBVIE INC. $0.2311/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104159228 CMS
ABBVIE INC. $2.1311/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104159220 CMS
ABBVIE INC. $14.5711/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104159222 CMS
ABBVIE INC. $0.6211/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104159216 CMS
ABBVIE INC. $13.7111/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104159218 CMS
PFIZER INC. $13.9411/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131197905 CMS
Ardelyx, Inc. $17.5511/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146691946 CMS
Lilly USA, LLC $19.3011/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135422155 CMS
PFIZER INC. $16.4810/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132084166 CMS
Janssen Biotech, Inc. $17.5210/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078370486 CMS
Regeneron Healthcare Solutions, Inc. $18.9710/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114098763 CMS
ABBVIE INC. $13.6610/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104159212 CMS
ABBVIE INC. $2.3910/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104159214 CMS
ABBVIE INC. $17.3609/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104159210 CMS
PFIZER INC. $17.8209/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131932914 CMS
Ardelyx, Inc. $15.5709/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146691944 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.9408/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153631332 CMS
ABBVIE INC. $16.6508/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104159204 CMS
ABBVIE INC. $12.3008/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104159206 CMS
ABBVIE INC. $2.9408/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104159208 CMS
ABBVIE INC. $14.4908/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104159202 CMS
PFIZER INC. $17.8008/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131872231 CMS
Lilly USA, LLC $19.1508/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135428820 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.3508/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153763738 CMS
ABBVIE INC. $7.4408/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104159198 CMS
ABBVIE INC. $1.2208/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104159200 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $16.5907/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153697555 CMS
Gilead Sciences, Inc. $13.4507/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133772271 CMS
PFIZER INC. $18.8707/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131773343 CMS
Janssen Biotech, Inc. $15.7607/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078370557 CMS
Regeneron Healthcare Solutions, Inc. $19.1407/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114098761 CMS
Celgene Corporation $16.5507/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101109312 CMS
Intercept Pharmaceuticals, Inc. $19.4606/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113643295 CMS
Phathom Pharmaceuticals, Inc. $14.8306/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151088047 CMS
ABBVIE INC. $13.9205/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104159196 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.1105/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153433239 CMS
Celgene Corporation $16.4204/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101109308 CMS
ABBVIE INC. $14.1604/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104159194 CMS
Janssen Biotech, Inc. $16.2604/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078370686 CMS
ABBVIE INC. $7.7404/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104159192 CMS
Ferring Pharmaceuticals Inc. $14.3603/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137490365 CMS
Lilly USA, LLC $15.3403/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135433209 CMS
ABBVIE INC. $8.0903/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104159188 CMS
ABBVIE INC. $0.8003/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104159190 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $906.54 69
PY2020 $241.17 17
PY2021 $466.01 44
PY2022 $883.20 86
PY2023 $1,077.18 84
PY2024 $778.83 57
PY2025 $810.69 78

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $229,877.20 12

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

12 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ARGENX US, INC. $31,956.55 12/19/2025 Non-covered Recipient Entity
ADVANCING RESEARCH INTERNATIONAL LLC
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237145901
Principal investigator 1 ARGENX US, INC. $7,612.50 12/19/2025 Non-covered Recipient Entity
ADVANCING RESEARCH INTERNATIONAL LLC
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237145906
Principal investigator 1 ARGENX US, INC. $13,113.80 11/20/2025 Non-covered Recipient Entity
ADVANCING RESEARCH INTERNATIONAL LLC
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237145895
Principal investigator 1 ARGENX US, INC. $5,528.85 10/29/2025 Non-covered Recipient Entity
ADVANCING RESEARCH INTERNATIONAL LLC
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237145891
Principal investigator 1 ARGENX US, INC. $7,801.00 10/23/2025 Non-covered Recipient Entity
ADVANCING RESEARCH INTERNATIONAL LLC
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237145918
Principal investigator 1 ARGENX US, INC. $3,806.25 10/23/2025 Non-covered Recipient Entity
ADVANCING RESEARCH INTERNATIONAL LLC
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237145921
Principal investigator 1 ARGENX US, INC. $5,528.85 10/16/2025 Non-covered Recipient Entity
ADVANCING RESEARCH INTERNATIONAL LLC
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237145914
Principal investigator 1 ARGENX US, INC. $37,021.40 10/03/2025 Non-covered Recipient Entity
ADVANCING RESEARCH INTERNATIONAL LLC
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237145911
Principal investigator 1 ARGENX US, INC. $18,670.20 09/18/2025 Non-covered Recipient Entity
ADVANCING RESEARCH INTERNATIONAL LLC
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237145930
Principal investigator 1 ARGENX US, INC. $7,612.50 08/26/2025 Non-covered Recipient Entity
ADVANCING RESEARCH INTERNATIONAL LLC
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237145937
Principal investigator 1 ARGENX US, INC. $86,135.80 08/21/2025 Non-covered Recipient Entity
ADVANCING RESEARCH INTERNATIONAL LLC
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237145934
Principal investigator 1 ARGENX US, INC. $5,089.50 08/07/2025 Non-covered Recipient Entity
ADVANCING RESEARCH INTERNATIONAL LLC
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237145925